CNSP · CNS Pharmaceuticals, Inc.
Market Cap
$8.43M
Shares
1.46M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$15.85M
-6.7%
FY2025
Diluted EPS
-$35.75
+92.3%
FY2025
Operating Cash Flow
-$13.81M
+19.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|
| $10.11M | $9.77M | $9.29M | $14.1M | $9.3M | $9.81M | $5.06M | $1.85M | $21.27K | |
| $6.81M | $6.21M | $5.61M | $4.77M | $5.97M | $4.68M | $4.39M | $1.98M | $860.52K | |
| $16.92M | $15.99M | $14.9M | $18.87M | $15.27M | $14.49M | $9.45M | $3.83M | $881.79K | |
| -$16.92M | -$15.99M | -$14.9M | -$18.87M | -$15.27M | -$14.49M | -$9.45M | -$3.83M | -$881.79K | |
| $15.13K | $15.23K | $16.12K | $13.81K | $7027 | $9285 | $3264 | $26.15K | $28.62K | |
| $34.42K | — | — | $27.69K | $0 | — | — | — | — | |
| $215.81K | $136K | $44.14K | $13.88K | -$7027 | -$9285 | -$3264 | -$44.23K | -$6.51M | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$16.7M | -$15.85M | -$14.86M | -$18.85M | -$15.27M | -$14.5M | -$9.46M | -$3.88M | -$7.39M | |
| USD/shares | -$18.08 | -$35.75 | -$466.89 | -$150,109.32 | -$336,600.00 | -$495,000.00 | — | — | — |
| USD/shares | -$18.08 | -$35.75 | -$466.89 | -$150,109.32 | -$336,600.00 | -$495,000.00 | — | — | — |
| shares | — | 443.37K | 31.82K | 125.5833 | 45.3912 | 29.2814 | 18.4649 | 15.1643 | 11.6784 |
| shares | — | 443.37K | 31.82K | 125.5833 | 45.3912 | 29.2814 | 18.4649 | 15.1643 | 11.6784 |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 1.57×
EV/EBIT
—
P/E (TTM)
—
Peer median 2.91×
Peer medians compare against the 184 similar-size Biotechnology companies (of 514 listed).
Key facts
CIK
1729427
CUSIP
18978H508
13F (30d)
11 filings
10 filers
Visit website
Investor relations